Federal advisers to the Centers for Disease Control and Prevention (CDC) met on December 4–5, 2025, to scrutinize long-standing elements of the childhood immunization timetable, including the timing of the birth dose of hepatitis B. The Advisory Committee on Immunization Practices (ACIP) is reviewing the schedule that directs more than 30 doses protecting against over a dozen diseases, and discussing ingredients such as aluminum adjuvants. The convening has drawn support from vaccine critics aligned with Health and Human Services Secretary Robert F. Kennedy Jr. and sharp concern from mainstream public-health groups worried about falling childhood vaccination rates and new outbreaks. The meeting could yield changes that alter when or how pediatricians routinely vaccinate infants and young children.
Key Takeaways
- ACIP convened December 4–5, 2025, to evaluate the childhood vaccine schedule that currently includes more than 30 individual doses protecting against 12+ diseases.
- The committee is expected to consider delaying or changing the policy that recommends a hepatitis B vaccine dose within 24 hours of birth.
- A new working group will examine aluminum-containing adjuvants and whether specific formulations are linked to increased asthma risk — a question most public-health research does not support.
- Researchers reported an analysis estimating that delaying the birth hepatitis B dose by months could add more than $222 million in health-care costs annually and cause hundreds of preventable deaths each year.
- Administration changes in June 2025 replaced ACIP membership; several major medical organizations have publicly stated they no longer rely solely on the panel’s guidance.
- Public-health officials warn that any weakening of the schedule risks lower coverage and resurgence of measles, pertussis and other vaccine-preventable diseases amid recent upticks in cases.
- Some groups advocating change argue targeted maternal screening could substitute for universal newborn hepatitis B vaccination; many experts say universal newborn dosing prevents household and early-life transmission.
Background
The CDC’s Advisory Committee on Immunization Practices was established in 1964 and for decades provided the foundation for U.S. immunization policy. ACIP recommendations influence clinicians’ practices and insurers’ coverage, giving the panel outsized influence over childhood vaccination. Historically the committee worked closely with professional societies such as the American Academy of Pediatrics (AAP) and relied on CDC subject-matter expertise and long-term safety monitoring.
In June 2025, the Biden administration’s Health and Human Services leadership replaced ACIP members with a new slate of advisers, a move that eroded trust from many mainstream medical organizations. That turnover, and recent shifts in CDC statements about vaccines and autism, prompted independent groups — including the AAP, the American Academy of Family Physicians and a University of Minnesota initiative called the Vaccine Integrity Project — to issue parallel guidance in some states. The changes arrive while immunization rates have declined in parts of the U.S., coinciding with local outbreaks of measles and pertussis.
Main Event
The central focus of the December ACIP meeting was twofold: reassessing the timing of the hepatitis B birth dose and beginning a formal review of the entire childhood immunization schedule. Committee members discussed the rationale for universal newborn hepatitis B vaccination — a policy credited with dramatic reductions in pediatric HBV infection over the past 45 years — versus targeted maternal screening and selective infant dosing.
Discussion also turned to the mechanics of the schedule itself: whether combination vaccines such as MMR should be split into separate products, and whether spacing or delaying certain shots would be acceptable. Proponents of maintaining current practice emphasized that combination vaccines minimize visits and that splitting them could reduce uptake and increase missed doses.
Another agenda item was the safety profile of aluminum salts used as adjuvants in several long-used vaccines. A working-group document signaled investigators would consider whether either of two common aluminum adjuvants is associated with asthma risk, a hypothesis public-health authorities say lacks robust evidence. Committee deliberations included presentations summarizing long-term safety surveillance and comparative exposure data showing routine daily aluminum intake from food and environment far exceeds that from vaccines.
Analysis & Implications
If ACIP moves to delay universal hepatitis B vaccination at birth or to require formalized pre-vaccination counseling, clinical practice could change quickly because pediatricians typically follow ACIP guidance. Delaying the birth dose risks exposing infants during a window when household transmission can occur; modeling presented at ACIP estimated such a delay could add more than $222 million annually in direct health-care costs and lead to hundreds of additional deaths each year. Those figures reflect higher rates of chronic infection that raise long-term liver disease and cancer risk.
A shift away from combination vaccines such as MMR would likely increase the number of clinic visits and injections per child. Even modest increases in logistical burden historically correlate with lower completion rates for full vaccine series. Lower coverage creates conditions for outbreaks of highly contagious illnesses; public-health leaders emphasize that the current schedule balances optimal immune response timing with practical considerations to protect children at their most vulnerable ages.
Reviewing aluminum adjuvants could have far-reaching technical consequences. Aluminum salts have been used as vaccine adjuvants for decades to enhance immune response; removing them would require extensive reformulation, new trials and years of regulatory review. There are currently no ready-made aluminum-free equivalents for many formulations, meaning any policy to restrict their use would not produce immediate alternatives and could interrupt supply of critical vaccines.
Comparison & Data
| Topic | Figure |
|---|---|
| Routine doses on childhood schedule | More than 30 |
| Diseases targeted | 12+ |
| Estimated excess annual health-care cost if Hep B birth dose delayed | $222 million |
| Years universal Hep B policy in use | ~45 years |
The table compiles numerical points emphasized during the meeting and in related analyses. Those numbers are central to the cost-benefit and risk assessments clinicians and policymakers will weigh when deciding whether to alter practice. The modeling of excess costs cited a combination of projected case counts, chronic infection rates and long-term treatment costs.
Reactions & Quotes
“We’re now starting to see truth telling about vaccines,”
Mary Holland, Children’s Health Defense (advocacy group)
Mary Holland’s organization supports changes and framed the committee’s review as corrective. Her comments reflect advocacy views that question aspects of mainstream vaccine policy and favor more parental decision-making.
“This is a dangerous new phase in a campaign to replace scientific expertise with a personal agenda,”
Dr. Sean O’Leary, Pediatric Infectious Disease Specialist, University of Colorado Anschutz
Dr. O’Leary, who chairs the AAP committee on infectious diseases, and other mainstream experts warned the review could undermine public confidence and reverse decades of progress in preventing childhood infections.
“Universal vaccination has been the cornerstone of hepatitis B elimination efforts for decades,”
Eric Hall, Assistant Professor of Epidemiology, Oregon Health & Science University (academic)
Academic researchers who modeled the effects of delaying the hepatitis B birth dose emphasized long-term population health harms and increased health-care costs in their presentations to the committee.
Unconfirmed
- No formal ACIP recommendation to delay the hepatitis B birth dose had been posted publicly at the time of this report; proposed options under consideration were described in committee documents but not finalized.
- Claims that aluminum adjuvants cause asthma, autism or other chronic disorders remain unsupported by high-quality, large-scale studies and were not confirmed by the committee’s evidence reviews.
- Reports that the committee will immediately split combination vaccines such as MMR into separate mandated shots were speculative; committee members discussed the logistical implications but had not adopted a policy.
Bottom Line
The ACIP review represents a substantive reassessment of policies that have guided U.S. pediatric vaccination for decades. Even incremental changes to timing, combination formulations or adjuvant use would have practical and public-health consequences — from increased clinic visits and supply-chain complications to potential rises in preventable disease if coverage falls.
Watch for the committee’s formal votes and any rapid guidance released by the CDC, as well as independent recommendations from major medical societies. Policymakers, clinicians and parents will need clear, evidence-based communication to weigh risks and benefits; decisions made in the coming weeks could affect immunization practice and disease trends for years.
Sources
- NPR (news report summarizing ACIP meeting and reactions)
- CDC Advisory Committee on Immunization Practices (ACIP) (official CDC advisory committee information)
- American Academy of Pediatrics (AAP) (professional medical association statement and guidance)
- Children’s Health Defense (advocacy organization)